Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

SHOCKING: Aurobindo pharma | Mind Blowing Facts

Aurobindo Pharma gains over 3% as subsidiary launches generic Advair Diskus in US; stock up 41% YTD

Aurobindo Pharma shares rose sharply after its subsidiary Lannett Company launched the generic equivalent of Advair Diskus in the US. The inhalation product, available in two strengths, marks the first commercialised product from Aurobindo’s inhalation pipeline. The stock has gained 41.16% year-to-date in 2026.

The Economic Times

Stocks in news: HDFC Bank, Ola Electric Mobility, NBCC and Knowledge Realty Trust

Indian equity markets closed higher on Friday, ending a losing streak with IT stock gains. HDFC Bank's CEO will not seek reappointment, while Mahindra & Mahindra expanded its EV battery service. Ola Electric received incentives, and Knowledge Realty Trust saw an offer for sale launch. NBCC signed an infrastructure project…

The Economic Times

Quant Mid Cap Fund exits Anthem Biosciences and Lenskart Solutions, adds Cochin Shipyard and 4 others in July

Quant Mid Cap Fund exited Anthem Biosciences and Lenskart Solutions in July, while adding five new stocks including Cochin Shipyard, UPL and IPCA Laboratories. The fund also increased exposure to six stocks, including Adani Energy Solutions and Indus Towers. Its portfolio expanded to 23 stocks, with AUM at Rs 8,106…

The Economic Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Sun Pharma, Cipla & other pharma stocks shed over 2% as Trump announces up to 200% tariffs on generic drugs from 2028

Pharma stocks, including Sun Pharma, Cipla, Lupin and Dr Reddy's, fell up to 2.5% after US President Donald Trump announced a phased tariff plan on imported generic drugs. While generics will remain tariff-free for two years, duties will rise to 100% from August 2028 and 200% from August 2029, weighing…

The Economic Times

Quant Mid Cap Fund exits Reliance Industries and 3 others, adds BHEL, 1 other stock in June

Quant Mid Cap Fund exited Reliance Industries and three other stocks in June while adding BHEL and L&T Technology Services to its portfolio, according to ACE MF data. The fund sold 21.38 lakh RIL shares worth Rs 282 crore and also exited PB Fintech, Torrent Pharmaceuticals and Oracle Financial Services…

The Economic Times

LKP Securities’ top 3 picks: High-conviction breakout stocks targeting strong gains

Positive market sentiment is fueling selective stock opportunities, according to Rupak De of LKP Securities. He identifies Aegis Vopak, Lodha, and Aurobindo Pharma as prime short-term picks, citing strong technical indicators like chart breakouts and bullish RSI crossovers. The Nifty is eyeing higher levels, while the IT index shows signs…

The Economic Times

F&O Talk: Smallcap index better placed than Nifty, says Sudeep Shah; picks 9 stocks for next week

SBI Securities expects Nifty's breakout to strengthen if it crosses 24,450, opening the door to 24,900. While small-caps continue outperforming, Bank Nifty retains a positive bias. The brokerage also highlights Aurobindo Pharma, DLF, Titan and Oberoi Realty among top picks.

The Economic Times

Read news from The Economist, FT, and more,
with one subscription

Aurobindo Pharma US gets FTC nod for $250 million acquisition of Lannett Company

Aurobindo Pharma's US arm has secured Federal Trade Commission approval for its $250 million acquisition of Lannett Company. This strategic move, expected to conclude by June 2026, will bolster Aurobindo's complex generics and controlled substances portfolio, enhance its US manufacturing capabilities with Lannett's Indiana facility, and is projected to immediately…

The Economic Times

Aurobindo Pharma clears key US hurdle in Lannett acquisition, closing expected soon

Indian drug giant Aurobindo Pharma is set for a major US expansion. The company has received crucial antitrust clearance from the US Federal Trade Commission for its takeover of Lannett Company. This regulatory approval removes the final hurdle. The acquisition is expected to close by the end of June.

The Economic Times

Quant Mid Cap Fund adds Adani Energy and 4 others, exits Paytm and 3 more stocks in May

Quant Mid Cap Fund, managed by Sandeep Tandon, has strategically adjusted its portfolio in May. The fund added Adani Energy and four other stocks while exiting Paytm and three other companies. This move reflects a dynamic approach to capturing growth opportunities within the mid-cap segment.

The Economic Times

Quant Small Cap Fund raises stake in Adani Enterprises and 8 others, trims in Aurobindo Pharma and 4 more

Quant Small Cap Fund increased exposure to Adani Enterprises and eight other stocks in May while reducing holdings in Aurobindo Pharma and four more. The fund also added six new stocks, exited three positions and maintained a defensive tilt through a higher large-cap allocation.

The Economic Times

Stocks in news: Rajesh Exports, Lenskart, Suzlon Energy, Aurobindo Pharma, Tata Motors

Indian markets saw volatility and closed lower on Wednesday. Key companies are in focus due to significant developments. SoftBank reduced its stake in Lenskart. Sebi issued an interim order against Rajesh Exports. Tata Motors revised its Avinya EV strategy. Suzlon Energy is diversifying into battery storage. RIL's subsidiary signed MoUs…

The Economic Times

Rahul Shah bullish on pharma, sees Sun Pharma and Aurobindo as key large-cap plays

Indian equity markets show a mixed but improving consumption trend, with selective FMCG and premium retail outperforming. Page Industries is highlighted as a strong recovery story, while Nykaa and Honasa are viewed cautiously. The pharma sector continues its outperformance, with Sun Pharma and Aurobindo Pharma looking attractive.

The Economic Times

Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?

Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business improvements, better margins, and strong earnings, the pharma major's market cap surged. Analysts see further upside but advise caution with stop losses due to the steep rise.

The Economic Times

Get all your
news in one place.

100's of premium titles.
One news app.

The Economic Times

Quant Mid Cap Fund exits Lenskart Solutions and 2 other stocks, adds SAIL in April

Quant Mid Cap Fund exited Lenskart Solutions, NMDC and SBI Cards in April, while adding Steel Authority of India to its portfolio, the fund’s monthly disclosure showed. The fund also increased exposure to Reliance Industries and maintained holdings in several key stocks, as sector allocations shifted toward healthcare and metals.

Al Jazeera

India’s electoral bonds laundry: ‘Corrupt’ firms paid parties, got cleansed

From PM Modi’s BJP to the opposition Trinamool Congress, parties gained from donations that activists say were dubious.

The Hindu

The legal issues surrounding Arvind Kejriwal’s arrest | Explained

Arvind Kejriwal arrest: The Hindu explores the legal issues surrounding the arrest of Delhi CM Arvind Kejriwal by the ED, including what legal contentions have been raised during the proceedings and what do judicial precedents say?

The Hindu

Pradhan Mantri Hafta Vasuli Yojana | Congress' swipe at government over electoral bonds issue

Congress general secretary Jairam Ramesh accused the Modi government of “hafta vasuli” (extortion) and claimed that 21 firms facing investigations from the CBI, Enforcement Directorate or I-T have donated through electoral bonds.

Get all your
news in one place.

100's of premium titles.
One news app.

The Hindu

Aurobindo unit gets USFDA nod to market generic asthma medication

Aurobindo Pharma's subsidiary receives USFDA approval for generic asthma medication for children. Product expected to launch in FY25 with estimated market size of $226.4M. Shares up 1.51% on BSE.

The Hindu

Pharma sector continues to create more jobs, says Aurobindo Pharma senior vice-president

Aurobindo Pharma Ltd. senior V-P U.N.B. Raju said Indian pharma sector will create more jobs and spur economic activity. He was handing out certificates to 30 students who completed a four-month training in pharma quality control.

The Times of India

Delhi liquor scam: CBI records Telangana CM KCR's daughter K Kavita's statement in Hyderabad

HYDERABAD: Central Bureau of Investigation (CBI) has recorded the statements of Telangana chief minister K Chandrashekar Rao's daughter Kalvakuntla Kavita in the Delhi Excise police scam on Sunday after questioning for seven hours.

The Hindu

Andhra Pradesh: Aurobindo Pharma conducts skill training for youth in Srikakulam

A four-month session was conducted by the firm and Ambedkar University

The Times of India

Aurobindo acquires domestic formulations business of group company Veritaz for Rs 171 crore

HYDERABAD: As part of its strategy to foray into the Indian formulations market, Hyderabad-based pharma major Aurobindo Pharma is acquiring the domestic formulations business of another Hyderabad-based company Veritaz Healthcare, which is promoted by its promoters, on a slump sale basis for a consideration of Rs 171 crore on a…

The Times of India

Aurobindo gets licence for supply of Pfizer’s Covid pill

HYDERABAD: Pharma major Aurobindo Pharma Limited has inked a sub-license agreement with the United Nations-backed public health organisation Medicines Patent Pool (MPP) for manufacturing and supplying a generic version of Pfizer’s oral Covid-19 treatment drug nirmatrelvir to 95 countries, including India.

People

Abhishek Manu Singhvi

Magunta Srinivasulu Reddy

12 stories

Peyush Bansal

10 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

United Nations

39,232 stories

Bharatiya Janata Party

Enforcement Directorate

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.